Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

HHS may reconsider 2022 Medicare premiums after cost cut for Alzheimer’s drug

January 11, 2022 Reprints

Biogen’s decision to halve the price of its controversial Alzheimer’s drug Aduhelm has the Biden administration rethinking the 15% hike for Medicare Part B premiums for 2022, Fierce Healthcare reports. Department of Health and Human Services Secretary Xavier Becerra announced Jan. 10 that he wants the Centers for Medicare and Medicaid Services to reassess its proposed price hike, which was based on an expected rise in drug costs, especially Aduhelm.

Help

HHS may reconsider 2022 Medicare premiums after cost cut for Alzheimer’s drug

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources